Ozuriftamab vedotin is an ADC designed to bind to ROR2 under low pH conditions of the tumor microenvironment, thus reducing off-target toxicity by sparing normal tissue and improving pharmacokinetics (84). The gene discussed is ROR2; the disease is neoplasm.